DRC Ebola Outbreak Pushes Bundibugyo-Specific Vaccine and Therapy Efforts
An ongoing Bundibugyo-strain Ebola outbreak in the DRC—the third-largest on record—has no approved strain-specific vaccine or treatment. The existing Zaire-targeted Ervebo vaccine may offer limited cross-protection, but data are scarce and safety in this outbreak is uncertain. New Bundibugyo-focused vaccines (including a vesicular stomatitis virus–based candidate) are in development, though clinical-grade material and human trials likely won’t be ready for six to nine months. Therapies such as remdesivir and the MBP134 monoclonal antibody cocktail show promise, but delivery and safety in the field pose challenges. Beyond vaccines and drugs, rapid diagnosis, isolation, contact tracing, and strong outbreak response remain essential tools for control.
